Filter by Category: In Vitro Activity

In Vitro Activity of Omadacycline and Comparators against Gram-positive and -Negative Isolates Collected from Patients in United States Medical Centers (2018): SENTRY Surveillance Program Results

In Vitro Activity of Omadacycline and Comparators against Gram-positive and -Negative Isolates Collected from Patients in United States Medical Centers (2018): SENTRY Surveillance Program Results. Lead author: MD Huband presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Friday-AAR-540

Update on the In Vitro Activity of Dalbavancin against Indicated Species (Staphylococcus aureus, Enterococcus Faecalis, β-Hemolytic Streptococci, and Streptococcus anginosus Group) Collected from United States Hospitals in 2017-2018

Update on the In Vitro Activity of Dalbavancin against Indicated Species (Staphylococcus aureus, Enterococcus Faecalis, β-Hemolytic Streptococci, and Streptococcus anginosus Group) Collected from United States Hospitals in 2017-2018. Lead author: HS Sader, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Friday-AAR-542

Comparison of the in vitro susceptibility of ceftolozane-tazobactam to the cumulative susceptibility rates of standard antibiotic combinations when tested against Pseudomonas aerugionsa from ICU patients with bloodstream infections or pneumonia.

Comparison of the in vitro susceptibility of ceftolozane-tazobactam to the cumulative susceptibility rates of standard antibiotic combinations when tested against Pseudomonas aerugionsa from ICU patients with bloodstream infections or pneumonia. by Shortridge D, Pfaller MA, Arends SJR, Raddatz J, DePestel DD and Flamm RK. published in Open Forum Infect. Dis. 20196 (6): ofz240

Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018).

Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018). by Sader HS, Flamm RK, Carvalhaes CG and Castanheira M. published in Diagn. Microbiol. Infect. Dis.: in press, 2019.

Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA and Europe (2014-17).

Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA and Europe (2014-17). by Carvalhaes CG, Sader HS, Flamm RK and Mendes RE. published in J. Antimicrob. Chemother.: in press, 2019.

In vitro activity of tedizolid in comparison with other oral and intravenous agents against a collection of community-acquired methicillin-resistant Staphylococcus aureus (2014-2015) in the United States.

In vitro activity of tedizolid in comparison with other oral and intravenous agents against a collection of community-acquired methicillin-resistant Staphylococcus aureus (2014-2015) in the United States. by Pfaller MA, Sader HS, Rhomberg PR, Flamm RK and Mendes RE. published in Microb. Drug Resist.: in press, 2019.

Comparative activity of ceftazidime-avibactam and ceftolozane-tazobactam against Enterobacteriaceae isolates producing extended-spectrum beta-lactamases from United States hospitals.

Comparative activity of ceftazidime-avibactam and ceftolozane-tazobactam against Enterobacteriaceae isolates producing extended-spectrum beta-lactamases from United States hospitals. by Castanheira M, Doyle TB, Mendes RE and Sader HS. published in Antimicrob. Agents Chemother.: in press, 2019.

Activity of tedizolid against gram-positive clinical isolates causing infections in Europe and surrounding areas (2014-2015).

Activity of tedizolid against gram-positive clinical isolates causing infections in Europe and surrounding areas (2014-2015). by Pfaller MA, Sader HS, Shortridge D, Castanheira M, Flamm RK and Mendes RE. published in J. Chemother. 2019; 13: 1-7

In vitro activity of plazomicin against Enterobacteriaceae isolates carrying genes encoding aminoglycoside-modifying enzymes most common in US Census divisions.

In vitro activity of plazomicin against Enterobacteriaceae isolates carrying genes encoding aminoglycoside-modifying enzymes most common in US Census divisions. by Castanheira M, Davis AP, Serio AW, Krause KM and Mendes RE. published in Diagn. Microbiol. Infect. Dis. 2019; 94 (1): 73-77.

In Vitro Activity of BWC0977 (a Novel Bacterial Topoisomerase Inhibitor) and Comparators against Recent Clinical and Molecularly Characterized Enterobacteriaceae and Non-Fermenter Isolates from the United States and Europe

In Vitro Activity of BWC0977 (a Novel Bacterial Topoisomerase Inhibitor) and Comparators against Recent Clinical and Molecularly Characterized Enterobacteriaceae and Non-Fermenter Isolates from the United States and Europe. Lead author: MD Huband, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1847